Roche tipped to be world's top drugmaker by 2014
Switzerland's Roche Holding AG is set to become the world's biggest drugmaker by sales in 2014, as current market leader Pfizer Inc skids down the rankings to sixth place, according to a study on Monday. The realignment of the global drugs industry reflects the looming "cliff" of patent expiries, which will see many of the world's top-selling medicines cannibalized by cheap generics over the next five years.
Forecasting company EvaluatePharma, which uses consensus analysts' sales estimates for its calculations, expects Roche to emerge as top dog in this tough new environment, reflecting its strength in fast-growing biotech drugs and its lack of near-term patent risks. Roche moved to consolidate its position in biotech-based cancer medicines last month by offering $43.7 billion to buy out the 44 percent of California-based Genentech Inc it does not already own. But even before that deal, which many investors expect to go through, albeit at a slightly sweetened price, Roche is on course to overtake all comers, with expected annual drug sales reaching $49.5 billion in 2014, EvaluatePharma said.
Do you want to know more?
Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.
Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.
Forecasting company EvaluatePharma, which uses consensus analysts' sales estimates for its calculations, expects Roche to emerge as top dog in this tough new environment, reflecting its strength in fast-growing biotech drugs and its lack of near-term patent risks. Roche moved to consolidate its position in biotech-based cancer medicines last month by offering $43.7 billion to buy out the 44 percent of California-based Genentech Inc it does not already own. But even before that deal, which many investors expect to go through, albeit at a slightly sweetened price, Roche is on course to overtake all comers, with expected annual drug sales reaching $49.5 billion in 2014, EvaluatePharma said.
Do you want to know more?
Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.
Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.
Comments